-
Patient Preference and Adherence
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine
Review
(2800) Views (674) Full article downloads
Authors: Daniel B Zandman, Mark A Peppercorn
Published Date March 2009
Volume 2009:3 Pages 87 - 92
DOI: http://dx.doi.org/10.2147/PPA.S3964
Daniel B Zandman, Mark A Peppercorn
Harvard Medical School, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA
Abstract: Mesalamine and its derivatives are effective and well-tolerated therapies for ulcerative colitis. However, patient adherence to traditional mesalamine-based therapy is poor, and is often limited by heavy pill burdens and frequent dosing intervals. This can lead to ineffective disease control, impaired quality of life, and preventable morbidity and mortality. Previous studies have suggested that a once-daily mesalamine regimen would be strongly adhered to in the outpatient setting, but at that time no such formulation of mesalamine existed. In 2007, clinical trial data showed a novel, once-daily, multi-matrix (MMX) formulation of mesalamine to be effective in both remission induction and remission maintenance. This breakthrough in drug delivery allowed the unification of an effective therapeutic with a formulation that enables outpatients to be increasingly adherent to their medication. In theory, this might result in improved outpatient disease control and a decreased number of flares. As the use of MMX mesalamine increases, studies examining the outpatient community adherence rate need to be performed.
Keywords: mesalamine, MMX, Lialda™, ulcerative colitis, inflammatory bowel disease, adherence
Other articles by Dr Mark Peppercorn
Readers of this article also read:
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Reducing adverse self-medication behaviors in older adults with the Next Generation Personal Education Program (PEP-NG): Design and methodology
Optimizing use of 5-ASA in the treatment of ulcerative colitis: Focus on patient compliance and adherence
Clinical management of smoking cessation: patient factors affecting a reward-based approach
Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs
Duloxetine in the management of diabetic peripheral neuropathic pain
Long-term adherence to CPAP treatment in patients with obstructive sleep apnea: importance of educational program
The MS Choices Survey: findings of a study assessing physician and patient perspectives on living with and managing multiple sclerosis
Impact of pharmacist interventions on patients' adherence to antidepressants and patient-reported outcomes: a systematic review
- 8th Annual Patient Adherence, Communications & Engagement Summit
31 May - 1 June 2011, Hotel Concorde, Berlin
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Health literacy and health seeking behavior among older men in a middle-income nation
- Increasing access to quality health care for the poor: Community perceptions on quality care in Uganda
- Prolonged rupture of membranes in term infants: should all babies be screened?
- Narcissistic rage: The Achilles’ heel of the patient with chronic physical illness




